Pinnacle 21 Releases P21 Community 4.0 Blog Post
As of 2022 年 4 月 25 日, we have released P21 Community 4.0 to general availability! Install it now from our Downloads page. P21C 4.0 is the first major release of this application…
Accelerating Oncology Drug Development with Biosimulation and Regulatory Strategy Page
Accelerating Oncology Drug Development with Biosimulation and Regulatory Strategy Trust the experts who advanced 500+ oncology projects With more than 80% of novel compounds to treat cancer coming from emerging...
PBPK Model Informs Antibody-Drug Conjugate Label for DDIs Without Clinical Trials Blog Post
Genentech was developing polatuzumab vedotin (Polivy), an anti-CD79b-vc-monomethyl auristatin E (MMAE) antibody-drug conjugate (ADC) to treat patients with transplantation-ineligible relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). MMAE is a potent...
Responsibility Page
Corporate Responsibility Certara is transforming drug development for good At Certara, we envision a future where drug development complexities are transformed into seamless, interconnected processes that bring impactful therapies to...
5 Reasons Why You Should Use Phoenix WinNonlin for PK/PD Analyses Blog Post
全球制药公司正面临药物开发周期日益延长与成本不断上升的挑战。Each step of drug development must therefore be as accurate and efficient as…
Privacy Policy Notice for the National Health Data System (SNDS) of France Page
Privacy Policy Notice for the National Health Data System (SNDS) of France
eChalk Talk: How Oncology Drug Developers Can Prepare for FDA’s Project Optimus Blog Post
Historically, the dosing strategy for oncology drugs has focused on use of the maximum tolerated dose. This has resulted in drugs’ pharmacokinetic (PK) profiles, pharmacokinetic/pharmacodynamic (PK/PD) relationships, and clinical target…
Certara Selected by the European Medicines Agency to Provide Real World Solutions for Critical Regulatory Decisions Blog Post
Princeton, N.J., 2022 年 3 月 17 日 — Certara, Inc. today announced a four-year, framework service contract with the European Medicines Agency (EMA) to advance regulatory decision-making in the human medicines domain…
